argenx (ARGX) to Release Quarterly Earnings on Thursday

argenx (NASDAQ:ARGX) is projected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect argenx to post earnings of $0.98 per share and revenue of $678.52 million for the quarter.

argenx Stock Performance

NASDAQ ARGX opened at $626.13 on Tuesday. The firm has a 50-day moving average of $642.93 and a 200-day moving average of $588.61. argenx has a 52-week low of $349.86 and a 52-week high of $678.21.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $717.00 price target (up from $670.00) on shares of argenx in a report on Tuesday, January 14th. Deutsche Bank Aktiengesellschaft lowered argenx from a “hold” rating to a “sell” rating in a research note on Friday, January 17th. Evercore ISI boosted their price target on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Truist Financial reaffirmed a “buy” rating and issued a $700.00 price objective (up from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, William Blair raised argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and an average price target of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.